bladder cancer

News

Astellas/Seattle Genetics target advanced bladder cancer wit...

Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but the problem of low response rates remains. At the ASCO an

News

J&J gets US okay for first targeted bladder cancer drug

Johnson & Johnson’s Balversa has become the first targeted therapy for bladder cancer after an FDA approval at the tail end of last week for patients with mutations in the FGFR gene.

News

BMS and Infinity trial immunotherapy combo in bladder cancer

Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.

News

NICE rejects BMS immunotherapy in advanced bladder cancer

No review for three years after final guidance

News

Roche's Tecentriq gets three years to prove itself on Cancer...

Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund.

News